Clinical Trial Update: A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis [Phase 2]

View source ↗

Summary

Phase 2 study update for CAL101 in idiopathic pulmonary fibrosis (IPF) is listed as active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• CAL101 (idelalisib)

Snippet

Sponsor: Calluna Pharma AS | Conditions: Idiopathic Pulmonary Fibrosis | Phase 2 | Status: ACTIVE_NOT_RECRUITING